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Prognostic impact of progression to induction chemotherapy
and prior paclitaxel therapy in patients with germ cell tumors
receiving salvage high-dose chemotherapy in the last 10 years:
a study of the European Society for Blood and Marrow
Transplantation Solid Tumors Working Party
A Necchi1, R Miceli1, M Bregni2, C Bokemeyer3, LA Berger3, K Oechsle3, K Schumacher4, E Kanfer5, JH Bourhis6, C Massard6, D Laszlo7,
J Montoro7, A Flechon8, F Arpaci9, S Secondino10, P Wuchter11, P Dreger11, M Crysandt12, N Worel13, W Kruger14, M Ringhoffer15,
A Unal16, A Nagler17, A Campos18, A Wahlin19, M Michieli20, G Sucak21, I Donnini22, R Schots23, N Ifrah24, M Badoglio25, M Martino26,
D Raggi1, P Giannatempo1, G Rosti27, P Pedrazzoli10 and F Lanza28 on behalf of the EBMT Solid Tumors Working Party
Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the
regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors. Twenty European
Society for Blood and Marrow Transplantation centers contributed data on patients treated between 2002 and 2012. Paclitaxel used
in either prior lines of therapy or in induction-mobilization regimens was considered. Multivariable Cox analyses of prespecified
factors were undertaken on PFS and overall survival (OS). As of October 2013, data for 324 patients had been contributed to this
study. One hundred and ninety-two patients (59.3%) had received paclitaxel. Sixty-one patients (19%) had a progression to
induction chemotherapy, 234 (72%) a response (29 (9%) missing or granulocyte colony-stimulating factor without chemotherapy).
Both progression to induction chemotherapy and prior paclitaxel were significantly associated with shorter OS univariably
(Po0.001 and P= 0.032). On multivariable analysis from the model with fully available data (N= 216) progression to induction was
significantly prognostic for PFS and OS (P= 0.003), but prior paclitaxel was not (P= 0.674 and P= 0.739). These results were
confirmed after multiple imputation of missing data. Progression to induction chemotherapy could be demonstrated as an
independent prognostic factor, in contrast to prior paclitaxel.
Bone Marrow Transplantation advance online publication, 7 December 2015; doi:10.1038/bmt.2015.300
INTRODUCTION
High-dose chemotherapy (HDCT) with hematopoietic stem cell
support is a therapeutic option for germ cell tumors (GCTs) used
since the late 1980s. It is a recognized therapeutic option in the
salvage setting since the last few years, based on the results of
two large retrospective series and a prospective clinical trial.1–4
These studies showed that a large proportion of patients could be
rescued by HDCT even if they had failed two or more
chemotherapy regimens or in spite of yielding poor prognostic
features. As a result, the number of HDCT performed in Europe has
dramatically increased in the last years, up to the average of 550
transplants per year (corresponding to 260 patients/year) as it
emerges from the European Society for Blood and Marrow
Transplantation (EBMT) database (Figure 1).
Although there is much controversy about the role of dose-
intensification in the first-salvage setting,5 there are many fewer
doubts in regards to the use of HDCT beyond the second-line
whenever it is feasible. However, it is likely that the heterogeneity
of these patients warrants a careful patient selection for HDCT
with the aim to improve the outcomes. The International
Prognostic Factor Study Group (IPFSG) classification is available
for patients undergoing first-salvage chemotherapy.6 Although
response to prior chemotherapy has been included in this score as
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well as in other series,1,7 that of response to induction/
mobilization regimen preceding single or multiple HDCT cycles
is unknown. Moreover, paclitaxel-based regimens are now
commonly employed for second- or third-line salvage therapy of
GCT,8 and their prognostic impact on the results of subsequent
salvage HDCT in these patients is unknown as well.
The objective of this retrospective study was to evaluate the
prognostic impact of response to induction chemotherapy
administered as part of the HDCT strategy as well as of prior
paclitaxel-containing chemotherapy. The hypothesis was that
these additional factors might be useful to improve the available
prognostic models and might be applied in prospective studies
of HDCT.
PATIENTS AND METHODS
Study design and patient population
The number of transplants performed each year for GCT in the EBMT
network currently relies on the minimum essential data-A forms.
Unfortunately these forms, which are routinely centralized to EBMT offices
from the certified centers, were not suitable for the purposes of the
present study because of the lack of the vast majority of required clinical
information. Hence, centers that were contributing data to EBMT were
selected based on their expertise in GCT treatment. The principal selection
criterion was 20 patients treated with HDCT in the last 10 years. Principal
investigators from these centers were asked to fill in uniform data fields,
comprising baseline characteristics and pathology information, induction/
mobilization treatments, and HDCT regimen using a study-specific Excel
sheet, after approval of each institutional review board and ethics
committee. Quality control and check for consistency were made by the
EBMT Office in Paris. Inclusion criteria for the current analysis were the
following: the administration of salvage HDCT between the years 2002 and
2012, male gender, minimum age of 18 at first transplant, either gonadal or
extragonadal origin, administration of induction chemotherapy before
HDCT (i.e. cases who were mobilized without chemotherapy were
excluded), the administration of paclitaxel in any lines before HDCT. The
use of paclitaxel in induction regimens before HDCT was also included.
Induction chemotherapy was referred to as any regimen administered with
debulking and/or mobilization purposes whenever HDCT was planned.
Patients were defined as responders if they had achieved at least stable
disease (that is, CR, partial response with normal/normalized markers
(PRm-), partial response with markers still elevated (PRm+) or stable
disease) or as having a progression to induction otherwise. CR was defined
as no clinically or radiographically detectable disease and normal/
normalized serum tumor markers. Disease progression was defined as
growing non-teratomatous masses or an increase of serum tumor marker.
Chemosensitivity was defined according to the response to the lines of
therapy preceding HDCT and following the conventional definition in use:
disease was considered cisplatin refractory when at least a tumor
stabilization or a remission had been achieved, but progression
occurred again within 4 weeks of the last cisplatin administration.
Disease progressing during chemotherapy was defined as absolute
refractoriness.7,9
Statistical analysis
The main study end points were PFS and overall survival (OS). OS was
defined as the time between the start of first HDCT and death from any
cause; time was censored at the date of last follow-up for patients
remaining alive. PFS was the time between the start of first HDCT and the
date of disease progression or death without progression, whichever
occurred first; time was censored at the date of last follow-up for patients
alive without progression. PFS and OS curves were estimated with the
Kaplan–Meier method and the log-rank test was used for subgroup
comparison. Multivariable analyses based on Cox regression models
were also undertaken to evaluate the prognostic association between
OS and PFS and the following prespecified prognostic covariates:
year of transplant, primary tumor site, International Germ Cell Cancer
Collaborative Group (IGCCCG) risk category,10 chemosensitivity, number of
prior chemotherapy regimens, response to induction chemotherapy,
paclitaxel-based chemotherapy before HDCT and taxane-based HDCT
regimen.
Some covariates presented with missing data and this reduced the
complete data set for model fitting. As a consequence, the number of
events was lowered, and although for the PFS model it was still adequate
to the degrees of freedom (d.f.) according to the Peduzzi’s strategy,11 for
OS the number of deaths was slightly lower the cutoff of 10 per d.f. Thus, in
addition to the analysis on the subset of patients with complete data, we
decided to fill covariate missing data by applying a multiple imputation





























































Figure 1. Number of high-dose chemotherapy courses (within the column) and transplanted patients (bottom) for germ cell tumor per year.
*Complete data not yet available for 2014. A full color version of this figure is available at the Bone Marrow Transplantation journal online.
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method.13 We generated 50 completed data sets; the MI models contained
all the covariates, together with the log-cumulative hazard of death and
progression (details on request).
The binary associations between the covariates were tested using
the exact χ2 test. The association between response to induction
chemotherapy and the transplant setting (that is, number of prior
chemotherapy regimens) was also investigated in a multivariable logistic
regression model, with adjustment for the other covariates; missing values
were assigned to an additional category. The statistical analyses were
performed using the SAS and R software (Institute for Statistics and
Mathematics of WU (Wirtschaftsuniversität), Wien, Austria; the R Project for
Statistical Computing. http://www.r-project.org/, last access 15 April 2015).
We considered a statistical test as significant when the corresponding
P-value was o5%.
RESULTS
Patient characteristics and treatment
As of October 2013, 324 patients from 20 centers and 7 countries
contributed data on either response to induction chemotherapy
or prior taxanes (Supplementary Table 1). Characteristics of
patients, disease and treatments are summarized in Table 1. The
median age of the cohort was 33 years (interquartile range (IQR):
26–40), the majority of cases (137, 42.3%) had a poor risk disease
at the GCT diagnosis, and 159 patients overall (49.1%) had
received HDCT in the third-line setting or beyond. Overall, 192
(59.3%) had received paclitaxel and 61 (18.8%) had a disease
progression to induction chemotherapy. Seventy-six patients
(23.4%) had received taxane-containing HDCT, consisting of
paclitaxel in 70 patients and docetaxel in six patients only.
Response, survival and prognostic factors
Overall, 175 patients (54.0%) achieved a CR or PRm- to HDCT and
75 (23.2%) were surgically resected after HDCT (25 (33.3%)
yielding fibrosis and necrosis). No significant association was
found between prior paclitaxel and response (that is, CR/PRm-)
to HDCT (P= 0.811). Response to induction chemotherapy was
significantly associated to response to HDCT (Po0.001), and to
the number of prior lines of therapy preceding HDCT both
univariably (P= 0.001) and multivariably (P= 0.031, Supplementary
Table 2).
Median follow-up was 36 months (IQR: 19–70). Overall, 179
patients had a progression and 150 died. Two-year PFS of patients
who had a response to induction chemotherapy was 42.4% (95%
confidence interval (CI): 36.3–49.5), whereas it was 22.5% (95% CI:
13.9–36.4) for those who had a progression to induction
(Po0.001, Figure 2a). Two-year OS was 58.7% (95% CI:
52.2–66.0) and 31.9% (95% CI: 21.6–47.1), respectively (Po0.001,
Figure 2b). Two-year PFS of patients who had received paclitaxel
before HDCT was 35.2% (95% CI: 28.9 to 42.9), whereas it was
40.9% (95% CI: 33.1–50.5) for those who had not (P= 0.182,
Figure 2c). Two-year OS was 49.9% (95% CI: 42.8–58.2) and 58.8%
(95% CI: 50.5– 68.5), respectively (hazard ratio (HR): 1.44, 95% CI:
1.03–2.01, P= 0.034, Figure 2d). PFS and OS curves in the
population obtained when excluding taxane-based HDCT
(N= 248) are provided as Supplementary Figures 1a and b
(P= 0.087 and P= 0.018, respectively). Clinical outcome according
to the line of HDCT is shown in Figures 3a and b. In particular,
2-year PFS was 43.9% (95% CI: 36.7–52.6), 35.2% (95% CI:
26.9–46.1) and 23.8% (95% CI: 14.9–38.1) in the second-line,
third-line and beyond the third-line, respectively.
Results of the multivariable analyses for PFS are shown in
Table 2. In the model with fully available data (N= 216) the
primary tumor site (overall P= 0.043), IGCCCG category (overall
P= 0.048), and progression to induction chemotherapy (HR: 1.92,
95% CI: 1.24–2.98, P= 0.003) were significantly prognostic, and
results were largely confirmed in the model with MI of missing
data. For OS, IGCCCG category (overall P= 0.048), taxane-based
HDCT (HR: 2.61, 95% CI: 1.18 –5.76, P= 0.017) and progression to
induction chemotherapy (HR: 2.09, 95% CI: 1.27–3.42, P= 0.003)
were significant predictors (Table 3). Results were confirmed for
the latter in the model with MI of missing data.
Table 1. Patient and disease characteristics pre-HDCT
No. %
Total number of patients 324 -
Transplant period 2002–2012





Other unspecified 11 3.4
Missing data 7 2.2
Histology
Pure seminoma 39 12.1
Nonseminoma or mixed germ cell tumors 258 79.6
Missing data 27 8.3
IGCCCG prognostic category
Good prognosis 55 17.0
Intermediate prognosis 47 14.5
Poor prognosis 137 42.3
Missing data 85 26.2
Disease chemosensitivity before mobilization
Refractory/absolutely refractory 110 34.0
Chemosensitive 211 65.1




Beyond third-line 57 17.6
Paclitaxel-based chemotherapy before HDCT
Yes 192 59.3
No 132 40.7
Response to induction/mobilization chemotherapy
Response/stable disease to induction 234 72.2
Progression to induction 61 18.8
Not applicable (GCSF only) 22 6.8









Other mixed regimens 34 10.5
GSCF only 22 6.8





Taxane-containing (paclitaxel, docetaxel) HDCT 76 23.4
Other 10 3.1
Abbreviations: CarboPEC= carboplatin, etoposide, cyclophosphamide;
CE= carboplatin, etoposide; CEI= carboplatin, etoposide, ifosfamide;
GCSF=granulocyte colony-stimulating factor; HDCT= high-dose
chemotherapy; IGCCCG= International Germ Cell Cancer Cooperative
Group; IQR= interquartile range.
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DISCUSSION
The current analysis attempted to address the prognostic impact
of two potentially useful factors in the clinical care of patients with
GCT receiving salvage HDCT. Although the prior administration of
paclitaxel was significantly prognostic for OS at univariable
analysis, it was not significant at the multivariate level. It is likely
that the univariable result was partly influenced by the possibility
to administer more active salvage therapies to taxane-free
patients after failure of HDCT, but details about the subsequent
therapies beyond progression to HDCT have not been captured in
this database. Most importantly, progression to induction
chemotherapy consistently emerged as a detrimental factor on
both PFS and OS after HDCT.
Among the patients selected for the analysis, missing data for
the variables utilized in the multivariable analysis were not
infrequent; however, the results were consistent across the
models with full and imputed data.
Owing to the unavailability of relevant clinical information for all
transplanted patients in the EBMT framework, the selection bias
that might have resulted from the present study is a concern that
cannot be fully addressed. However, in order to minimize the risk
of such a bias, a selection of centers based on their expertise in
GCT was made, assuring that these centers are currently following
or contributing to make international guidelines in this disease.
Also, the baseline characteristics of the analyzed cohort were
those typical of relapsed GCT patients.
Other potentially confounding factors should be acknowledged:
first, the detrimental effect of progression to induction chemo-
therapy could be assessed only in patients who actually had








































































































Figure 2. (a) Kaplan–Meier curves of PFS according to response to induction chemotherapy. Legend: continuous line: progression; dotted line:
response. (b) Kaplan–Meier curves of overall survival according to response to induction chemotherapy. Legend: continuous line: progression;
dotted line: response. (c) Kaplan–Meier curves of PFS according to prior paclitaxel chemotherapy. Legend: continuous line: no; dotted line: yes.
(d) Kaplan–Meier curves of overall survival according to prior paclitaxel chemotherapy. Legend: continuous line: no; dotted line: yes.
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with disease progression have likely been excluded from HDCT.
This is the reason why a disease progression to induction
chemotherapy was reported in only a very small proportion of
patients (18.8%). Second, the present analysis was lacking of a
comparison with an alternative conventional-dose strategy, and
we could not make any recommendation regarding the most
effective treatment for patients with a chemoresistant disease. The
assessment of chemoresistance provided here would need a
prospective validation through a trial design similar to that of the
Groupe d’Etude des Tumeurs Urogénitales-13 trial whereby the
intensity of treatment (that is, dose-dense regimen vs standard
chemotherapy) was based on the early assessment of the kinetics
of tumor marker decline.14 However, the number of available
patients will hardly allow running such a study design in the
salvage setting.
Third, patients who had not received any chemotherapy for
mobilization or debulking purposes, and who had been mobilized
with granulocyte colony-stimulating factors only (6.8%), were
excluded from the study. Nevertheless, a few important observa-
tions can be made from the current analysis. Although there is a
general agreement in favor of the use of HDCT in relapsing
patients, available results should be critically reviewed according
to chemoresistance, mostly referred to as either PD as best




































































Figure 3. (a) Kaplan–Meier curves of PFS according to the line of HDCT. (b) Kaplan–Meier curves of overall survival according to the line
of HDCT.
Table 2. Results of multivariable Cox analyses of PFS
Factor Patients with full data (N=216),
model without MI
All patients (N=324), model with MI
HR 95% CI P-valuea HR 95% CI P-valuea
Year of transplant 0.289 0.912
2008–2012 vs 2002–2007 0.77 0.47–1.25 0.98 0.68–1.41
Tumor primary site 0.043 0.044
Gonadal vs retroperitoneal 1.44 0.83–2.49 1.19 0.76–1.86
Mediastinal vs retroperitoneal 2.70 1.33–5.49 2.08 1.14–3.80
Other vs retroperitoneal 1.19 0.32–4.52 0.67 0.26–1.78
IGCCCG category 0.048 0.059
Intermediate vs good 1.22 0.68–2.19 1.29 0.79–2.10
Poor vs good 1.76 1.08–2.86 1.65 1.07–2.52
Disease chemosensitivity 0.668 0.536
Chemorefractory vs chemosensitive 0.92 0.63–1.34 1.11 0.80–1.52
Transplant setting 0.338 0.138
3rd Line vs 2nd line 1.38 0.89–2.14 1.19 0.84–1.68
43rd Line vs 2nd line 1.35 0.72–2.50 1.52 1.01–2.29
Response to induction chemotherapy 0.003 0.022
Progression vs response/stable disease 1.92 1.24–2.98 1.55 1.07–2.26
Paclitaxel-based chemotherapy before HDCT 0.674 0.694
Yes vs no 1.10 0.70–1.73 1.07 0.77–1.49
Taxane-containing HDCT 0.840 0.320
Yes vs no 1.07 0.55–2.07 1.25 0.81–1.94
Abbreviations: CI= confidence interval; HDCT=high-dose chemotherapy; HR=hazard ratio; IGCCCG= International Germ Cell Cancer Cooperative Group;
MI=multiple imputation of missing data. aP: two-sided Wald test P-value.
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high-risk categories of the IPFSG classification. Despite the global
favorable survival estimates, only a small proportion of patients
with the above characteristics could be ultimately rescued
according to the available series.15 In clinical practice, response
to induction chemotherapy, when applicable, could help to refine
the prognostic ability of the available models and should be
included in the guidance for patient selection and counseling as
well. Results from subset analyses of large prospective trials will be
able to corroborate the present findings and are required before
incorporate response to induction chemotherapy as a prognostic
factor for the next studies. The opening phase 3 study of
conventional-dose chemotherapy (TIP: paclitaxel, ifosfamide and
cisplatin) vs high-dose chemotherapy (TI-CE: paclitaxel and
ifosfamide, followed by high-dose carboplatin and etoposide) as
first-salvage therapy of GCT (TIGER trial) will serve as an ideal
platform to this aim.
Unfortunately, we were unable to capture the information on
the number of cycles of induction chemotherapy that had been
administered in each case. This information is critical since, by
definition, induction chemotherapy entails the administration of
1–2 cycles of standard dose chemotherapy for mobilization and
debulking purposes. Nevertheless, the timing of HDCT delivery
(that is, sequentially after the end of the induction course in each
case) lends confidence to the reliability of response to induction
chemotherapy as an independent prognostic factor that can be
more impactful than response to the prior lines of chemotherapy.
Indeed, the timing of response assessment before HDCT has
emerged as the most critical prognostic factor in GCT. Although
we have not recorded how progression to induction chemo-
therapy has been assessed in each case, it is likely that it was
based on rising serum tumor marker only in most cases. Rising
serum tumor marker during induction chemotherapy is an
important parameter of reduced efficacy of HDCT to be
considered. In parallel, we were able to provide an updated
outcome assessment of HDCT in the salvage setting of GCTs. We
collected a large number of patients who have been given HDCT
in the community framework, that is, outside of clinical trials or
single institution series for this disease. Although the outcomes in
the second-line setting paralleled those obtained in a recent
retrospective study,2 we were also able to analyze the outcome
beyond the second-line setting (N= 159), an area for which
available results are biased by limited numbers.
More than one-third of patients who had received HDCT in the
third-line benefited from a sustained PFS, and up to 24% of those
who had received HDCT beyond the third-line. Among these
patients, long-term OS was 45% in the third-line and 35% beyond
the third-line. These results do confirm those obtained in the
cohort of 49 patients who had been treated with tandem
high dose (HD)-carboplatin and etoposide in the third-line or
beyond at the Indiana University.1
In conclusion, in this analysis we observed that the results of
HDCT as salvage therapy administered in the last 10 years were
not influenced by the increasing use of paclitaxel-containing
salvage chemotherapy preceding HDCT. Most importantly, we
have observed a significant negative prognostic impact of disease
progression to induction chemotherapy that may justify why a
number of such patients are not administered HDCT in clinical
practice.
Globally, HDCT (namely tandem or triple cycle of
HD-carboplatin and etoposide) confirms to be a substantially
effective strategy once one or multiple chemotherapy regimens
have failed.
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Table 3. Results of multivariable Cox analyses of overall survival
Factor Patients with full data (N=216),
model without MI
All patients (N= 324), model with MI
HR 95% CI P-valuea HR 95% CI P-valuea
Year of transplant 0.276 0.742
2008–2012 vs 2002–2007 1.45 0.74–2.81 1.07 0.70–1.65
Tumor primary site 0.142 0.294
Gonadal vs retroperitoneal 1.58 0.79–3.20 1.07 0.64–1.79
Mediastinal vs retroperitoneal 2.43 1.00–5.94 1.31 0.63–2.75
Other vs retroperitoneal 0.43 0.05–3.64 0.34 0.09–1.33
IGCCCG category 0.048 0.227
Intermediate vs good 1.07 0.54–2.11 1.29 0.74–2.23
Poor vs good 1.51 0.86–2.67 1.53 0.94–2.48
Disease chemosensitivity 0.229 0.047
Chemorefractory vs chemosensitive 1.31 0.84–2.04 1.46 1.01–2.13
Transplant setting 0.340 0.167
3rd Line vs 2nd Line 1.39 0.81–2.38 1.23 0.82–1.85
43rd Line vs 2nd Line 1.65 0.80–3.40 1.57 0.98–2.52
Response to induction chemotherapy 0.003 0.035
Progression vs response/stable disease 2.09 1.27–3.42 1.64 1.04–2.60
Paclitaxel-based chemotherapy before HDCT 0.739 0.586
Yes vs no 1.09 0.64–1.86 1.12 0.75–1.66
Taxane-containing HDCT 0.017 0.010
Yes vs no 2.61 1.18–5.76 1.88 1.17–3.04
Abbreviations: CI= confidence interval; HDCT=high-dose chemotherapy; HR=hazard ratio; IGCCCG= International Germ Cell Cancer Cooperative Group;
MI=multiple imputation of missing data. aP: two-sided Wald test P-value.
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